Posted inClinical Updates Wellness & Lifestyle
Optimizing Twice-Daily Thoracic Radiotherapy Dosage in Limited-Stage Small-Cell Lung Cancer: Impact on Survival and Toxicity
A phase II trial reveals that high-dose twice-daily thoracic radiotherapy (60 Gy/40 fractions) significantly improves survival without increasing severe toxicity compared to the standard dose (45 Gy/30 fractions) in limited-stage SCLC patients.